Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody

Journal of the National Cancer Institute

Volumn 97, Issue 1, 2005, Pages 14-21

  Pytowski, Bronislaw ^a   Goldman, Jeremy ^b   Persaud, Kris ^a   Wu, Yan ^a   Witte, Larry ^a   Hicklin, Daniel J ^a   Skobe, Mihaela ^c   Boardman, Kendrick C ^b   Swartz, Melody A ^b,d  

^a ELI LILLY AND COMPANY   (United States)

^b Northwestern University   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MF4 31C1; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FEMALE; GENE OVEREXPRESSION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHANGIOGRAPHY; MICROMORPHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RECEPTOR BLOCKING; SKIN; SURVIVAL; TAIL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHOGRAPHY; MICE; MICE, NUDE; PHOSPHORYLATION; RATS; TAIL; TIME FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 12444343144     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji003     Document Type: Article

References (32)

1. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling [comment]. J Natl Cancer Inst. 2002;94:819-25.
2. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 2002;16:922-34.
3. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50:3-20.
4. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.[erratum appears in EMBO J. 1996 Apr 1;15(7):1751; PMID: 8612600]. EMBO J. 1996;15:290-98.
5. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA. 1996;93:1988-92.
6. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997;16:3898-911.
7. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA. 1995;92:3566-70.
8. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001;20:672-682.
9. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-8.
10. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786-90.
11. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573-83.
12. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001; 20:4762-73.
13. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7:199-205.
14. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA. 2002;99:8868-73.
15. Kubo H, Fujiwara T, Jussila L, Hashi H, Ogawa M, Shimizu K, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000;96:546-53.
16. Persaud K, Tille JC, Liu M, Zhu Z, Jimenez X, Pereira DS, et al. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J Cell Sci. 2004;117(Pt 13):2745-56.
17. Boardman KC, Swartz MA. Lymphangiogenesis in a mouse tail. In: ASME / Bioengineering Division; 2001; Snowbird, UT: ASME; 2001.
18. Boardman KC, Swartz MA. Interstitial flow as a guide for lymphangiogenesis. Circ Res. 2003;92:801-8.
19. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990;63:185-194.
20. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, et al. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem. 1994;269:12456-61.
21. Harlow E, Lane D, editors. Antibodies: a laboratory manual. New York (NY): Cold Spring Harbor Laboratory; 1988.
22. Bussolino F, De Rossi M, Sica A, Colotta F, Wang JM, Bocchietto E, et al. Murine endothelioma cell lines transformed by polyoma middle T oncogene as target for and producers of cytokines. J Immunol. 1991;147:2122-9.
23. Swartz MA, Berk DA, Jain RK. Transport in lymphatic capillaries: I. Macroscopic measurment using residence time distribution analysis. Am J Physiol. 1996;270:H324-329.
24. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
25. Zhu Z, Bohlen P, Witte L. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr Cancer Drug Targets 2002;2:135-56. Review.
26. Erhard H, Rietveld FJ, Brocker EB, de Waal RM, Ruiter DJ. Phenotype of normal cutaneous microvasculature. Immumoelectron microscopic observations with emphasis on the differences between blood vessels and lymphatics. J Invest Dermatol. 1996;106:135- 40.
27. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997;276:1423-5.
28. Veikkola T. Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001;20: 1223-31.
29. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
30. Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, Pajusola K, et al. Lymphangiogenetic gene theraphy with minimal blood vascular side effects. J Exp Med. 2002;196:719-30.
31. Yoon YS, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C, et al. VEGF-C gene theraphy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003;111:717-25.
32. Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res. 2001;88:623-9.